MENU
+Compare
CYTK
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$33.16
Change
-$0.75 (-2.21%)
Capitalization
3.96B

CYTK Cytokinetics Forecast, Technical & Fundamental Analysis

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more

Industry: #Biotechnology
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CYTK with price predictions
Jun 27, 2025

CYTK in +3.84% Uptrend, rising for three consecutive days on June 13, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CYTK advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CYTK just turned positive on May 27, 2025. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 143 cases where CYTK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CYTK broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CYTK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). CYTK's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (200.000) is also within normal values, averaging (252.247).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CYTK is expected to report earnings to rise 4.41% to -141 cents per share on July 31

Cytokinetics CYTK Stock Earnings Reports
Q2'25
Est.
$-1.42
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.04
Q3'24
Missed
by $0.13
Q2'24
Missed
by $0.25
The last earnings report on May 06 showed earnings per share of -136 cents, beating the estimate of -137 cents. With 2.35M shares outstanding, the current market capitalization sits at 3.96B.
A.I. Advisor
published General Information

General Information

a company which engages in discovery and development of small molecule drug therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
350 Oyster Point Boulevard
Phone
+1 650 624-3000
Employees
564
Web
https://www.cytokinetics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTDCX16.100.09
+0.56%
Russell Inv Multifactor US Equity C
GSFPX17.490.08
+0.43%
Goldman Sachs US Eq Div and Premium P
VGSIX29.420.09
+0.31%
Vanguard Real Estate Index Investor
SDSCX30.370.06
+0.20%
BNY Mellon Sm/Md Cp Gr I
VVERX6.98N/A
N/A
Virtus Ceredex Small-Cap Value Eq R6

CYTK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IMVT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-2.21%
IMVT - CYTK
50%
Loosely correlated
-1.77%
IDYA - CYTK
47%
Loosely correlated
-4.13%
KRYS - CYTK
46%
Loosely correlated
-2.60%
DNLI - CYTK
44%
Loosely correlated
-2.69%
ROIV - CYTK
43%
Loosely correlated
-1.81%
More